<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<?covid-19-tdm?>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
<journal-title>Frontiers in Genetics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Genet.</abbrev-journal-title>
<issn pub-type="epub">1664-8021</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">773726</article-id>
<article-id pub-id-type="doi">10.3389/fgene.2021.773726</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications</article-title>
<alt-title alt-title-type="left-running-head">Cueno and Imai</alt-title>
<alt-title alt-title-type="right-running-head">Understanding SARS2 VOC Spike Glycoprotein</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cueno</surname>
<given-names>Marni E.</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/83596/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Imai</surname>
<given-names>Kenichi</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1089182/overview"/>
</contrib>
</contrib-group>
<aff>Department of Microbiology, Nihon University School of Dentistry, <addr-line>Tokyo</addr-line>, <country>Japan</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/994634/overview">Nimisha Ghosh</ext-link>, Siksha O Anusandhan University, India</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/393672/overview">Neetika Nath</ext-link>, Universit&#xe4;tsmedizin Greifswald, Germany</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/41594/overview">Kira Vyatkina</ext-link>, Saint Petersburg Academic University (RAS), Russia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Marni E. Cueno, <email>marni.cueno@nihon-u.ac.jp</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>773726</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Cueno and Imai.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Cueno and Imai</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Coronavirus disease 2019 (COVID-19) pandemic has been attributed to SARS-CoV-2 (SARS2) and, consequently, SARS2 has evolved into multiple SARS2 variants driving subsequent waves of infections. In particular, variants of concern (VOC) were identified to have both increased transmissibility and virulence ascribable to mutational changes occurring within the spike protein resulting to modifications in the protein structural orientation which in-turn may affect viral pathogenesis. However, this was never fully elucidated. Here, we generated spike models of endemic HCoVs (HCoV 229E, HCoV OC43, HCoV NL63, HCoV HKU1, SARS CoV, MERS CoV), original SARS2, and VOC (alpha, beta, gamma, delta). Model quality check, structural superimposition, and structural comparison based on RMSD values, TM scores, and contact mapping were all performed. We found that: 1) structural comparison between the original SARS2 and VOC whole spike protein model have minor structural differences (TM &#x3e; 0.98); 2) the whole VOC spike models putatively have higher structural similarity (TM &#x3e; 0.70) to spike models from endemic HCoVs coming from the same phylogenetic cluster; 3) original SARS2&#x20;S1-CTD and S1-NTD models are structurally comparable to VOC S1-CTD (TM &#x3d; 1.0) and S1-NTD (TM &#x3e; 0.96); and 4) endemic HCoV S1-CTD and S1-NTD models are structurally comparable to VOC S1-CTD (TM &#x3e; 0.70) and S1-NTD (TM &#x3e; 0.70) models belonging to the same phylogenetic cluster. Overall, we propose that structural similarities (possibly ascribable to similar conformational epitopes) may help determine immune cross-reactivity, whereas, structural differences (possibly associated with varying conformational epitopes) may lead to viral infection (either reinfection or breakthrough infection).</p>
</abstract>
<kwd-group>
<kwd>conformational epitopes</kwd>
<kwd>endemic HCoV</kwd>
<kwd>SARS-CoV-2</kwd>
<kwd>spike glycoprotein</kwd>
<kwd>variants of concern</kwd>
</kwd-group>
<contract-num rid="cn001">19K10078 19K10097</contract-num>
<contract-sponsor id="cn001">Japan Society for the Promotion of Science<named-content content-type="fundref-id">10.13039/501100001691</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Coronaviruses (CoV) are categorized as enveloped positive-stranded RNA viruses belonging to family Coronaviridae, order <italic>Nidovirales</italic>, and subfamily <italic>Othocoronavirinae</italic> comprising four genera (<xref ref-type="bibr" rid="B32">King et&#x20;al., 2018</xref>). Currently, seven human-infecting CoVs have been identified as early as the 1960s, namely: human CoV (HCoV)-229E (1962), HCoV-OC43 (1967), severe acute respiratory syndrome (SARS)-CoV 1 (SARS1) (2002), HCoV-NL63 (2004), HCoV-HKU1 (2005), and Middle East respiratory syndrome (MERS)-CoV (2012) [all six are endemic to the human population] with SARS-CoV 2 (SARS2) (2019) being the latest CoV capable of infecting humans (<xref ref-type="bibr" rid="B20">Hamre and Procknow, 1966</xref>; <xref ref-type="bibr" rid="B28">Kapikian et&#x20;al., 1969</xref>; <xref ref-type="bibr" rid="B34">Ksiazek et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B14">Fouchier et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B60">Woo et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B63">Zaki et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B65">Zhu et&#x20;al., 2020</xref>). Moreover, the spike (a common structural protein among the CoVs) is classified as a class I viral fusion protein involved in host tropism, viral entry and pathogenesis, and host immune response induction (<xref ref-type="bibr" rid="B39">Lu et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B43">Millet and Whittaker, 2015</xref>; <xref ref-type="bibr" rid="B26">Hulswit et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B38">Li, 2016</xref>). Additionally, the spike has three segments, namely: the large ectodomain which is divided into the S1&#x20;receptor-binding subunit (involved in viral attachment) and S2&#x20;membrane-fusion subunit (assists virus-cell fusion) (<xref ref-type="bibr" rid="B26">Hulswit et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B38">Li, 2016</xref>), single-pass transmembrane anchor, and short intracellular tail (<xref ref-type="bibr" rid="B38">Li, 2016</xref>).</p>
<p>Among the human-infecting CoVs, only SARS2 infection resulted to a pandemic causing the coronavirus disease 2019 (COVID-19) (<xref ref-type="bibr" rid="B54">Tay et&#x20;al., 2020</xref>). Moreover, multiple SARS2 variants were produced ascribable to various mutations occurring within the spike and, among the SARS2 variants produced, variants of concern (VOC) were identified to have increased transmissibility and virulence while having decreased response to available therapeutic strategies (<xref ref-type="bibr" rid="B33">Koyama et&#x20;al., 2020</xref>). Considering VOC are a product of mutational changes occurring within the spike and structural orientation modifications are a product of amino acid alterations which in-turn may affect viral pathogenesis (<xref ref-type="bibr" rid="B8">Chen and Bahar, 2004</xref>), we hypothesize that the VOC spike glycoprotein may have structural modifications that may affect both immune cross-reactivity and viral pathogenesis. However, this has likewise not been fully investigated. A better understanding of the possible structural differences and similarities occurring within the VOC spike proteins may give us a better understanding of the potential of cross-reactivity to occur and, likewise, could give a possible explanation for the occurrence of both SARS2 reinfection and breakthrough infections which in-turn may lead to novel therapeutic strategies.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>SARS2 VOC and HCoV Spike Modeling</title>
<p>Representative CoV spike amino acid sequences were collected from the National Center for Biological Information (NCBI) website. In order to obtain an accurately generated representative spike model, at least five sequence models were initially analyzed, whereby, spike models having similar Root Mean Square Deviation (RMSD) values and Template Modeling scores (TM-scores) based on superimposition done by TM-align (<xref ref-type="bibr" rid="B67">Zhang and Skolnick, 2005</xref>) were utilized for further downstream analyses. For generating SARS2 VOC spike models, the following representative amino acid sequences were used with Genebank accession number indicated: alpha (QTC11018), beta (QTJ24451), gamma (QRX39401), and delta (QUF59047). For generating the endemic HCoV spike models, the following representative amino acid sequences were used with Genebank accession number indicated: 229E (ABB90513), OC43 (AXX83297), NL63 (QED88040), HKU1 (ARB07617), SARS1 (AAR07625), MERS (AHX00731), and original SARS2 (YP_009724390). Similarly, representative original SARS2 spike S1&#x20;C-terminal domain (S1-CTD) and N-terminal domain (S1-NTD) models were generated based on UniProt reference number P0DTC2. All models generated were through the Phyre2 web server (<xref ref-type="bibr" rid="B29">Kelley and Sternberg, 2009</xref>) while Jmol applet (<xref ref-type="bibr" rid="B23">Herraez, 2006</xref>) was used for protein visualization.</p>
</sec>
<sec id="s2-2">
<title>Spike Model Quality Assessment</title>
<p>All CoV spike models generated throughout the study were initially assessed for quality before further downstream analyses. In this regard, protein model:crystal structure superimposition and contact mapping were performed. Representative crystal structure used for model quality comparison was the 2021 strain (PDB ID: 7BNM) which already has the D614G mutation (<xref ref-type="bibr" rid="B56">Tomaszewski et&#x20;al., 2020</xref>). Moreover, a monomeric 7BNM crystal model (based on the 7BNM crystal structure) was generated using Phyre2 and superimposed to the 7BNM crystal structure to likewise serve as an additional model quality check. Representative CoV spike models and crystal structure were superimposed using TM align (<xref ref-type="bibr" rid="B67">Zhang and Skolnick, 2005</xref>). For this study, we considered spike models as suitable for further downstream analyses if TM scores between superimposed sequence model:crystal structure, crystal model:crystal structure, and crystal model:sequence model are close to 1.0. Subsequently, CMView applet (Contact type: C&#x3b1;; Distance cut-off: 8.0; Needleman-Wunsch alignment) was used to determine protein common contact among the superimpositions made (<xref ref-type="bibr" rid="B57">Vehlow et&#x20;al., 2011</xref>). Briefly, higher common contact would indicate that there is more structural similarities between the superimposed models and crystal structure (<xref ref-type="bibr" rid="B25">Holm and Sander, 1996</xref>) which in-turn implies that the generated spike models are suitable for further downstream analyses.</p>
</sec>
<sec id="s2-3">
<title>CoV Spike Model Comparison</title>
<p>Three different sets of protein structural differentiation were performed: 1) whole protein structural comparison among VOC spike models, whereby, all generated models were compared (RMSD value, TM score, common contact) to the original SARS2 and among VOC spike models through superimposition and contact mapping;2) whole protein structural comparison between VOC and endemic HCoVs spike models, whereby, generated VOC spike models were compared (RMSD value, TM score, common contact) to generated endemic HCoV spike models also through superimposition and contact mapping; and 3) spike domain structural comparison, whereby, generated S1-CTD and S1-NTD models derived from the VOC and endemic HCoV spike models were compared (TM score only) through original SARS2:VOC and VOC:endemic HCoV superimposition. RMSD value, Tm score, and protein common contact were established using TM align and CMView, respectively.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Generated Spike Models Are Fit for Downstream Analyses</title>
<p>Model quality assessment has been highly recommended before performing any downstream structural analyses using generated protein structures from either experimental (i.e. crystallized) or theoretical (i.e. computer-based) approaches (<xref ref-type="bibr" rid="B3">Berman et&#x20;al., 2006</xref>). To determine the quality and correctness of all spike models generated, both protein structural superimpositions and contact mapping were done. Representative SARS2 crystal structure (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>), generated SARS2 crystal model (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>) and SARS2 sequence model (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>) were all utilized for superimposition. We found that TM scores between crystal structure:crystal model [TM (based on the crystal structure): 0.94939] (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>), crystal structure:sequence model [TM (based on the crystal structure): 0.94992] (<xref ref-type="fig" rid="F1">Figure&#x20;1E</xref>), and crystal model:sequence model [TM (based on the crystal model): 0.99508] (<xref ref-type="fig" rid="F1">Figure&#x20;1F</xref>) were TM &#x3e; 0.90 which we considered adequate for further analyses (<xref ref-type="bibr" rid="B24">Hevener et&#x20;al., 2009</xref>). Additionally, protein contact mapping between crystal structure:crystal model [common contact: 86.2%] (<xref ref-type="fig" rid="F1">Figure&#x20;1G</xref>), crystal structure: sequence model [common contact: 86.2%] (<xref ref-type="fig" rid="F1">Figure&#x20;1H</xref>), and crystal model:sequence model [common contact: 98.8%] (<xref ref-type="fig" rid="F1">Figure&#x20;1I</xref>) have high common contact (&#x3e;85%), thereby, insinuating that there is high protein contact similarity between the structures. Taken together, these results would suggest that the generated spike models are fit for further downstream structural analyses.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Quality check of generated monomeric SARS2 spike protein models. Representative SARS2&#x20;<bold>(A)</bold> 7BNM crystal <bold>(B)</bold> 7BNM model, and <bold>(C)</bold> sequence model of monomeric spike proteins are presented. Superimposition between <bold>(D)</bold> 7BNM crystal and 7BNM model <bold>(E)</bold> 7BNM crystal and sequence model, and <bold>(F)</bold> 7BNM model and sequence models are shown. TM scores relative to the 7BNM crystal (when superimposed with either the 7BM model or sequence model) and 7BNM model (when superimposed with the sequence model) of the superimposed protein structures are indicated below. SARS2 7BNM crystal (green), 7BNM model (blue), and sequence model (pink) are presented.</p>
</caption>
<graphic xlink:href="fgene-12-773726-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Original SARS2 and VOC Spike Models Putatively Have Minor Structural Differences</title>
<p>Both protein structure and conformation dynamics are associated to biological function (<xref ref-type="bibr" rid="B8">Chen and Bahar, 2004</xref>). To establish the possible spike structural variations among the VOC, spike models of each VOC (alpha, beta, gamma, delta) and the original SARS2 were superimposed and analyzed using RMSD values, TM scores, and contact map overlap (CMO) analyses. Measurements involving RMSD values focus on similarities between superimposed atomic coordinates (including amino acid residues), whereas, measurements involving TM scores focus on similarities between protein structures regardless of protein size (<xref ref-type="bibr" rid="B67">Zhang and Skolnick, 2005</xref>; <xref ref-type="bibr" rid="B35">Kufareva and Abagyan, 2012</xref>). Additionally, common contacts obtained through CMO analyses provide information related to pairwise spatial and functional relationship of residues within a protein while unifying certain features related to protein folding and structure prediction (<xref ref-type="bibr" rid="B59">Wang and Xu, 2013</xref>; <xref ref-type="bibr" rid="B4">Bittrich et&#x20;al., 2019</xref>). Original SARS2 and VOC spike models used were generated by Phyre2 (<xref ref-type="sec" rid="s10">Supplementary Figure&#x20;S1</xref>). As seen in <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, alpha, gamma, and delta variants are possibly similar with the original SARS2 (RMSD &#x3c;1.00), whereas, the beta variant has a higher structural difference compared to the original SARS2 and other VOC (RMSD &#x3e;1.00). These observations are likewise generally consistent with TM scores (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). Moreover, CMO analyses between the original SARS2 and VOC showed similar common contact (95%) between the original and both alpha (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) and beta (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>) variants while both gamma (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>) and delta (<xref ref-type="fig" rid="F2">Figure&#x20;2F</xref>) variants had higher common contact at 100 and 99.5%, respectively. Taken together, we hypothesize that no major structural difference within the spike glycoprotein occurred among the original SARS2, alpha, gamma, and delta variants (RMSD &#x3c;1.00; TM &#x3e; 0.99), whereas, the beta variant putatively may have differed with regards to atomic coordinates when compared to the original SARS2 and VOC (RMSD &#x3e;1.00). However, considering TM score, we likewise presume that no major structural difference occurred in the beta variant (TM &#x3e; 0.98). Furthermore, similar common contact between the alpha and beta variants could suggest similar functional residues in both variants, whereas, the close to similar common contact (0.5% difference) between gamma and delta variants may likewise imply that functional residues are somewhat the same albeit with some minor difference. These results are consistent with SARS2 maintaining its genomic integrity across propagation (<xref ref-type="bibr" rid="B42">Mercatelli and Giorgi, 2020</xref>) and varying VOC transmissibility (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>). In this regard, we postulate that the overall spike model among VOC generally did not have a major deviation in terms of protein structural conformation from the original SARS2 spike model. Nevertheless, the minor structural deviation observed may contribute to each VOC having a unique biological characteristic especially in terms of viral transmissibility and immune evasion consistent with an earlier report (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>) showing that the effective reproduction numbers of the VOC differ among themselves, namely: alpha (4% compared to alpha), beta (4% compared to beta), gamma (10% compared to alpha; 17% compared to beta), and delta (55% compared to alpha; 60% compared to beta; 34% compared to gamma).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Structural comparison of the original SARS2 and VOC spike models based on the whole protein. <bold>(A)</bold> RMSD values and <bold>(B)</bold> TM scores of superimposed spike models are tabulated. TM scores normalized to a spike model are distinguished by the presence or absence of a parenthesis. Contact maps of the <bold>(C)</bold> original SARS2 and alpha variant <bold>(D)</bold> original SARS2 and beta variant <bold>(E)</bold> original SARS2 and gamma variant, and <bold>(F)</bold> original SARS2 and delta variant are shown. Common contact of the protein structures being compared are labeled below. Contacts present in both protein structures (black) and present in one of the protein structures [either pink (first protein structure uploaded: original SARS2) or green (second protein structure uploaded: VOC)] are indicated.</p>
</caption>
<graphic xlink:href="fgene-12-773726-g002.tif"/>
</fig>
<p>It is worth mentioning that the spike model of the gamma variant potentially has similar atomic coordinates (RMSD value), protein structure (TM score), and functional residues (CMO analyses) when compared to the original SARS2 spike model. Considering the gamma variant is more transmissible compared to the original SARS2 (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>), we hypothesize that the biological difference between the gamma variant and original SARS2 in terms of spike function is mainly associated with amino acid residue changes and not on protein structural variations. Additionally, it is also worth mentioning that individuals infected with the beta variant have a higher chance of needing critical care and death occurrence compared to infections associated with alpha, gamma, and delta variants (<xref ref-type="bibr" rid="B6">Callaway, 2021</xref>) possibly due to high levels of immune evasion associated to the beta variant (<xref ref-type="bibr" rid="B41">Madhi et&#x20;al., 2021</xref>). In this regard, we think that the difference in atomic coordinates of the beta variant (RMSD &#x3e;1.00) compared to the other VOC (RMSD &#x3c;1.00) is a contributing factor in COVID-19 infection severity. Admittedly, additional work is needed to further explore these two points.</p>
</sec>
<sec id="s3-3">
<title>VOC Spike Models May Have Varying Structural Similarity to Endemic HCoVs</title>
<p>Among the known endemic HCoVs, both 229E and NL63 strains are classified under the alpha-CoV phylogenetic cluster while the other remaining strains are classified under the beta-CoV phylogenetic cluster which is further divided into lineages, specifically: OC43 and HKU1 belong to the A lineage; SARS1 and SARS2 belong to the B lineage; and MERS belong to the C lineage (<xref ref-type="bibr" rid="B20">Hamre and Procknow, 1966</xref>; <xref ref-type="bibr" rid="B28">Kapikian et&#x20;al., 1969</xref>; <xref ref-type="bibr" rid="B34">Ksiazek et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B9">Chiu et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B60">Woo et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B37">Letko et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B65">Zhu et&#x20;al., 2020</xref>). To determine the potential spike structural differences and similarities between VOC and endemic HCoVs, model superimposition and analyses (RMSD values, TM scores, and CMO analyses) were performed. All endemic HCoV spike models were generated by Phyre2 (<xref ref-type="sec" rid="s10">Supplementary Figure&#x20;S2</xref>). In terms of atomic coordinates (RMSD values), we found that VOC spike models differed (RMSD &#x3e;2.6) from endemic HCoVs (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). However, in terms of protein structure (TM scores), we observed that VOC spike models (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>) potentially have similar protein structural conformation (TM &#x3e; 0.50) (<xref ref-type="bibr" rid="B62">Yang et&#x20;al., 2015</xref>). Moreover, VOC spike models putatively have high structural similarity when compared to endemic HCoVs in the same phylogenetic cluster [SARS1 (TM &#x3e; 0.90), OC43 (TM &#x3e; 0.85), HKU1 (TM &#x3e; 0.849), MERS (TM &#x3e; 0.70)] while those in a different phylogenetic cluster have lower structural similarity [229E (TM &#x3e; 0.569), NL63 (TM &#x3e; 0.57)]. Interestingly, in terms of CMO analyses, we found that endemic HCoV spike models have the same common contact difference when compared to spike models from the alpha (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>) and beta (<xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>) variants which we suspect to be due to alpha and beta variants having putatively the same functional residues (common contact) consistent with our earlier results (<xref ref-type="fig" rid="F2">Figures 2C,D</xref>) and reported biological characteristics wherein effective reproduction numbers between the two variants are the same (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>). In contrast, both gamma (<xref ref-type="fig" rid="F3">Figure&#x20;3E</xref>) and delta (<xref ref-type="fig" rid="F3">Figure&#x20;3F</xref>) variants have varying common contact when compared to the endemic HCoV spike models which we likewise believe to be attributable to the difference in functional residues between the two variants consistent with our earlier results (<xref ref-type="fig" rid="F2">Figures 2E,F</xref>) and reported biological characteristics wherein the effective reproduction numbers of both gamma and delta variants differ between the two (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>). Noticeably, VOC spike models have high common contact (74.2&#x2013;74.6%) with SARS1 which coincidentally belongs to the same lineage as that of SARS2. This would emphasize the close structural dynamics between SARS1 and VOC spike models which we attribute to high nucleotide similarity (<xref ref-type="bibr" rid="B48">Robson, 2020</xref>). Taken together, we postulate that the overall VOC spike models have varying atomic coordinates and functional residues while generally having the same protein structural conformation when compared to the endemic HCoV spike models.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Structural comparison of the original SARS2 and endemic HCoV spike models based on the whole protein. <bold>(A)</bold> RMSD values and <bold>(B)</bold> TM scores of superimposed spike models are tabulated. TM scores normalized to a spike model is distinguished by the presence or absence of a parenthesis. Contact maps of the <bold>(C)</bold> alpha variant relative to other endemic HCoV <bold>(D)</bold> beta variant relative to other endemic HCoV <bold>(E)</bold> gamma variant relative to other endemic HCoV, and <bold>(F)</bold> delta variant relative to other endemic HCoV are shown. Common contact of the protein structures being compared are labeled below. Endemic HCoVs [HCoV 229E (229E), HCoV OC43 (OC43), HCoV NL63 (NL63), HCoV HKU1 (HKU1), SARS-CoV-1 (SARS1), and MERS CoV (MERS)] are indicated. Contacts present in both protein structures (black) and present in one of the protein structures [either pink (first protein structure uploaded: VOC) or green (second protein structure uploaded: endemic HCoV)] are presented.</p>
</caption>
<graphic xlink:href="fgene-12-773726-g003.tif"/>
</fig>
<p>Considering the results at this point (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>), we wish to highlight that data obtained from RMSD values, TM score, and CMO analyses were all based on superimposing full-length CoV spike protein models. However, since it is probable that the protein structural dynamics along a receptor binding site may be composed of different atomic coordinates (particularly, protein length and structure) while having a similar binding surface (<xref ref-type="bibr" rid="B13">Di Rienzo et&#x20;al., 2017</xref>) [consistent with what we observed (TM &#x3e; 0.98) (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>)], further structural comparison is merited which would mainly focus on both S1-CTD and S1-NTD of the VOC spike models.</p>
</sec>
<sec id="s3-4">
<title>VOC S1-CTD and S1-NTD Models Are Structurally Comparable to the Original SARS2 and Endemic HCoV</title>
<p>S1 subunit of CoV spike glycoproteins is made up of the C-terminal domain (S1-CTD) and N-terminal domain (S1-NTD) which in-turn have been associated to host cell binding (<xref ref-type="bibr" rid="B26">Hulswit et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B38">Li, 2016</xref>). To elucidate the structural similarities and differences within the SARS2&#x20;S1-CTD and S1-NTD, VOC S1-CTD and S1-NTD models were superimposed with models from the original SARS2 and endemic HCoV. Structural analyses were done using TM score measurements. Surprisingly, when comparing the original SARS2 and VOC S1-CTD models, we found that they are structurally similar (TM &#x3d; 1.00) (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). Moreover, ocular inspection of the model superimposition between the original SARS2 and VOC S1-CTD models showed no difference (<xref ref-type="fig" rid="F4">Figures 4B&#x2013;E</xref>). SARS2 pathogenesis and host tropism were linked to the SARS2&#x20;furin-like cleavage site (FLC) (<xref ref-type="bibr" rid="B61">Xing et&#x20;al., 2020</xref>), however, protein structural analyses have shown that the SARS2&#x20;S1-CTD [alternatively known as the receptor binding domain (RBD)] is unaffected in the absence of the SARS2 FLC (<xref ref-type="bibr" rid="B11">Cueno et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B45">Papa et&#x20;al., 2021</xref>). This emphasizes the structural importance of maintaining the structural conformation of the SARS2&#x20;S1-CTD with regards to viral pathogenesis and host tropism consistent with our results. In this regard, we postulate that regardless of successive SARS2 variants being generated, S1-CTD would most likely maintain its structural conformation. In contrast, we observed that the original SARS2 and VOC S1-NTD models had varying structural differences (TM &#x3e; 0.95) (<xref ref-type="fig" rid="F4">Figure&#x20;4F</xref>) which can be further seen upon ocular inspection of the model superimposition between the original SARS2 and VOC S1-NTD models (<xref ref-type="fig" rid="F4">Figures 4G&#x2013;J</xref>). Mutations along the S1-NTD have been linked to viral escape from humoral immune response (<xref ref-type="bibr" rid="B19">Graham et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B30">Kemp et&#x20;al., 2021</xref>) and S1-NTD was shown to bind to heme metabolites (in particular to biliverdin and bilirubin) which has been proposed to have a role in immune evasion (<xref ref-type="bibr" rid="B49">Rosa et&#x20;al., 2021</xref>). This could putatively mean that structural alterations within the S1-NTD may contribute to immune evasion. Admittedly, additional experimentation is needed to further prove this&#x20;point.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Structural comparison of the VOC spike models relative to the original SARS2 and endemic HCoV based on S1-CTD and S1-NTD models. (A&#x2013;J) Original SARS2 and VOC. <bold>(A)</bold> TM scores of superimposed S1-CTD models. TM scores normalized to a spike model are distinguished by the presence (original SARS2) or absence (VOC) of a parenthesis. Structural superimposition of SARS2&#x20;S1-CTD models between <bold>(B)</bold> original SARS2 and alpha variant <bold>(C)</bold> original SARS2 and beta variant <bold>(D)</bold> original SARS2 and gamma variant, and <bold>(E)</bold> original SARS2 and delta variant are shown. <bold>(F)</bold> TM scores of superimposed S1-NTD models. TM scores normalized to a spike model are distinguished by the presence (original SARS2) or absence (VOC) of a parenthesis. Structural superimposition of SARS2&#x20;S1-NTD models between <bold>(G)</bold> original SARS2 and alpha variant <bold>(H)</bold> original SARS2 and beta variant <bold>(I)</bold> original SARS2 and gamma variant, and <bold>(J)</bold> original SARS2 and delta variant are shown. Original SARS2 is colored magenta while the VOC is colored cyan. <bold>(K&#x2013;L)</bold> VOC and endemic HCoV. <bold>(K)</bold> TM scores of superimposed S1-CTD models. TM scores normalized to VOC models. <bold>(L)</bold> TM scores of superimposed S1-NTD models. TM scores normalized to VOC models. Endemic HCoVs [HCoV 229E (229E), HCoV OC43 (OC43), HCoV NL63 (NL63), HCoV HKU1 (HKU1), SARS-CoV-1 (SARS1), and MERS CoV (MERS)] are indicated.</p>
</caption>
<graphic xlink:href="fgene-12-773726-g004.tif"/>
</fig>
<p>Subsequently, when comparing VOC and endemic HCoV S1-CTD models, we noted a consistent structural difference (<xref ref-type="fig" rid="F4">Figure&#x20;4K</xref>) which we ascribe to VOC S1-CTD models being structurally similar (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). On the other hand, when VOC and endemic HCoV S1-NTD models were structurally compared (<xref ref-type="fig" rid="F4">Figure&#x20;4L</xref>), we likewise observed varying structural differences consistent with our earlier results (<xref ref-type="fig" rid="F4">Figure&#x20;4F</xref>). Noticeably, both S1-CTD and S1-NTD models belonging to the same phylogenetic cluster (SARS1, OC43, HKU1, MERS) possibly have the same structural conformation (TM &#x3e; 0.50) (<xref ref-type="bibr" rid="B62">Yang et&#x20;al., 2015</xref>) with the VOC S1-CTD and S1-NTD models, respectively. These results are consistent with our earlier work and further emphasizes the possibility of the receptor binding structural conformation (S1-CTD and S1-NTD) being somewhat conserved in the same phylogenetic cluster and lineage (<xref ref-type="bibr" rid="B10">Cueno and Imai, 2021</xref>).</p>
<p>It is worth mentioning that gamma and delta S1-NTD models have similar TM scores (<xref ref-type="fig" rid="F4">Figure&#x20;4F</xref>) when compared to the original SARS2&#x20;S1-NTD insinuating that both variants have similar S1-NTD structural conformation. Considering both S1-CTD and S1-NTD models are structurally similar between the gamma and delta variants while having varying viral transmissibility (<xref ref-type="bibr" rid="B7">Campbell et&#x20;al., 2021</xref>), we hypothesize that amino acid residue changes unique in each variant play a significant role in contributing to viral pathogenesis (<xref ref-type="bibr" rid="B21">Harvey et&#x20;al., 2021</xref>). In a possible future work, it would be interesting to test this hypothesis.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>SARS2 genome has mutated consistently with genetic changes occurring almost every week (<xref ref-type="bibr" rid="B12">Day et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B42">Mercatelli and Giorgi, 2020</xref>). Similarly, nonsynonymous nucleotide changes occurred which in-turn causes amino acid changes (<xref ref-type="bibr" rid="B12">Day et&#x20;al., 2020</xref>). Additionally, these mutations are either high-effect (contribute to viral adaptation and fitness) or low-effect mutations (deleterious and rapidly purged) (<xref ref-type="bibr" rid="B15">Frost et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B21">Harvey et&#x20;al., 2021</xref>). Moreover, heavily mutated SARS2 lineages have emerged since the original SARS2 was detected in December 2019 giving rise to VOC (<xref ref-type="bibr" rid="B21">Harvey et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B51">Sanyaolu et&#x20;al., 2021</xref>). Throughout this study, we attempted to show that VOC spike models have structural similarities and differences with the original SARS2 and endemic HCoV spike models.</p>
<p>Spike protein binding is the initial step in all CoV infections which is why it is the first CoV antigen targeted by the immune system (<xref ref-type="bibr" rid="B26">Hulswit et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B38">Li, 2016</xref>; <xref ref-type="bibr" rid="B50">Salvatori et&#x20;al., 2020</xref>). In general, epitopes found along antigen regions are classified as either sequential (continuous or linear amino acid stretch) or conformational (discontinuous amino acid stretch) epitopes (<xref ref-type="bibr" rid="B27">Jerne, 1960</xref>; <xref ref-type="bibr" rid="B2">Benjamin et&#x20;al., 1984</xref>; <xref ref-type="bibr" rid="B17">Gershoni et&#x20;al., 2007</xref>). Moreover, antigen:antibody complexes formed are mainly composed of conformational epitopes (&#x223c;90%) (<xref ref-type="bibr" rid="B22">Haste Andersen et&#x20;al., 2006</xref>). Additionally, antibody paratopes found in the antibody variable region primarily identify and interact with antigen epitopes thereby forming epitope:paratope complementarity which goes beyond amino acid sequence recognition but instead protein structure dynamics (<xref ref-type="bibr" rid="B58">Vojtek et&#x20;al., 2019</xref>). Furthermore, every antibody paratope could interact with multiple antigen epitopes which in-turn could induce a polyclonal immune response resulting to cross-reactivity (<xref ref-type="bibr" rid="B52">Sewell, 2012</xref>; <xref ref-type="bibr" rid="B58">Vojtek et&#x20;al., 2019</xref>). These would highlight the potential significance of protein structure formation (particularly conformational epitopes) when considering SARS2 immune response induction. In fact, it was found that viral epitopes (such as Influenza and CMV) that lack sequence identity with SARS2 are able to stimulate an immune response (<xref ref-type="bibr" rid="B66">Mahajan et&#x20;al., 2021</xref>) which we believe is attributable to similar protein structural formation. In this regard, we postulate that high VOC S1-CTD and S1-NTD structural similarity (TM &#x3e; 0.70) with either the original SARS2 or endemic HCoV could putatively have cross-reactivity with the original SARS2 and endemic HCoV spike models (<xref ref-type="bibr" rid="B36">Ladner et&#x20;al., 2021</xref>) possibly ascribable to having multiple similar conformational epitopes that are considered valuable in neutralizing viral pathogenesis (<xref ref-type="bibr" rid="B31">Khare et&#x20;al., 2021</xref>). This is consistent with previous work showing that T&#x20;cell frequencies against the original SARS2 have likewise been correlated to VOC (<xref ref-type="bibr" rid="B53">Stankov et&#x20;al., 2021</xref>) which we suspect to be due to structural similarity (particularly S1-CTD). Moreover, VOC have been shown to partially escape humoral immune response, however, VOC are found to be unable to escape cellular immune response among convalescent donors and vaccinees (<xref ref-type="bibr" rid="B16">Geers et&#x20;al., 2021</xref>). This would highlight the putative significance of cellular immune response [particularly Th1 and Tfh cells (<xref ref-type="bibr" rid="B47">Poland et&#x20;al., 2020</xref>) ] in providing lasting protection against VOC and, more importantly, the T cell-recognizing conformational epitopes that can counteract viral infectivity (<xref ref-type="bibr" rid="B31">Khare et&#x20;al., 2021</xref>).</p>
<p>It is worth mentioning that VOC emergence is distinguished by having reduced susceptibility to polyclonal antibody responses which can potentially lead to increased reinfections or breakthrough infections (<xref ref-type="bibr" rid="B16">Geers et&#x20;al., 2021</xref>). In this regard, we speculate that both reinfections and breakthrough infections are ascribable to T cell-recognizing conformational changes along the VOC spike glycoprotein [particularly S1-NTD (<xref ref-type="bibr" rid="B19">Graham et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B30">Kemp et&#x20;al., 2021</xref>)]. Admittedly, these speculations would need both laboratory and clinically-derived data to&#x20;prove.</p>
<p>In summary, we putatively showed that: 1) minor structural differences occur in the whole original SARS2 and VOC spike protein model; 2) the whole VOC spike models possibly have differing structural similarity to spike models from endemic HCoVs, wherein, those belonging in the same phylogenetic cluster have high structural similarities while those belonging in a different phylogenetic cluster have low structural similarities; 3) original SARS2&#x20;S1-CTD and S1-NTD models are structurally similar to VOC S1-CTD and S1-NTD models; and 4) endemic HCoV S1-CTD and S1-NTD models are structurally similar to VOC S1-CTD and S1-NTD models belonging to the same phylogenetic cluster. Overall, we propose that structural similarities (possibly ascribable to similar conformational epitopes) may help determine immune cross-reactivity, whereas, structural differences (possibly associated with varying conformational epitopes) may lead to viral infection (either reinfection or breakthrough infection)</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by the JSPS KAKENHI Grant Numbers 19K10078 and 19K10097, Uemura Fund provided by the Dental Research Center, Nihon University School of Dentistry, and Nihon University Multidisciplinary Research Grant for 2021.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2021.773726/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2021.773726/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material>
<label>Supplementary Figure&#x20;S1</label>
<caption>
<p>Generated spike homology models related to SARS2 and VOC. <bold>(A)</bold> original SARS2, <bold>(B)</bold> alpha variant, <bold>(C)</bold> beta variant, <bold>(D)</bold> gamma variant, and <bold>(E)</bold> delta variant.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure&#x20;S2</label>
<caption>
<p>Generated spike homology models related to endemic HCoV. <bold>(A)</bold> HCoV 229E, <bold>(B)</bold> HCoV OC43, <bold>(C) </bold>HCoV NL63, <bold>(D)</bold> HCoV HKU1, <bold>(E)</bold> SARS CoV, and <bold>(F)</bold> MERS&#x20;CoV.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Presentation1.PPTX" id="SM1" mimetype="application/PPTX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benjamin</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Berzofsky</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>East</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Gurd</surname>
<given-names>F. R. N.</given-names>
</name>
<name>
<surname>Hannum</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>S. J.</given-names>
</name>
<etal/>
</person-group> (<year>1984</year>). <article-title>The Antigenic Structure of Proteins: a Reappraisal</article-title>. <source>Annu. Rev. Immunol.</source> <volume>2</volume>, <fpage>67</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.02.040184.000435</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Burley</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sali</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adzhubei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bourne</surname>
<given-names>P. E.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Outcome of a Workshop on Archiving Structural Models of Biological Macromolecules</article-title>. <source>Structure</source> <volume>14</volume>, <fpage>1211</fpage>&#x2013;<lpage>1217</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2006.06.005</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bittrich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Labudde</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>StructureDistiller: Structural Relevance Scoring Identifies the Most Informative Entries of a Contact Map</article-title>. <source>Sci. Rep.</source> <volume>9</volume>, <fpage>18517</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-55047-4</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callaway</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Remember Beta? New Data Reveal Variant&#x27;s Deadly powers</article-title>. <source>Nature</source>. <pub-id pub-id-type="doi">10.1038/d41586-021-02177-3</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Laurenson-Schafer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jinnai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Konings</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at June 2021</article-title>. <source>Euro Surveill.</source> <volume>26</volume>, <fpage>2100509</fpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.24.2100509</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Bahar</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Mining Frequent Patterns in Protein Structures: a Study of Protease Families</article-title>. <source>Bioinformatics</source> <volume>20</volume>, <fpage>i77</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bth912</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiu</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Man Poon</surname>
<given-names>L. L.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Human Coronavirus NL63 Infection and Other Coronavirus Infections in Children Hospitalized with Acute Respiratory Disease in Hong Kong, China</article-title>. <source>Clin. Infect. Dis.</source> <volume>40</volume>, <fpage>1721</fpage>&#x2013;<lpage>1729</lpage>. <pub-id pub-id-type="doi">10.1086/430301</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cueno</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses</article-title>. <source>Front. Med.</source> <volume>7</volume>, <fpage>594439</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.594439</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cueno</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iguchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yasumaru</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Insights on the Structural Variations of the Furin-like Cleavage Site Found Among the December 2019-July 2020 SARS-CoV-2 Spike Glycoprotein: A Computational Study Linking Viral Evolution and Infection</article-title>. <source>Front. Med.</source> <volume>8</volume>, <fpage>613412</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2021.613412</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Day</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gandon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lion</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>S. P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>On the Evolutionary Epidemiology of SARS-CoV-2</article-title>. <source>Curr. Biol.</source> <volume>30</volume>, <fpage>R849</fpage>&#x2013;<lpage>R857</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2020.06.031</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Rienzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Milanetti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lepore</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Olimpieri</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Tramontano</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Superposition-free Comparison and Clustering of Antibody Binding Sites: Implications for the Prediction of the Nature of Their Antigen</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>45053</fpage>. <pub-id pub-id-type="doi">10.1038/srep45053</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fouchier</surname>
<given-names>R. A. M.</given-names>
</name>
<name>
<surname>Hartwig</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Bestebroer</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Niemeyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>De Jong</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>A Previously Undescribed Coronavirus Associated with Respiratory Disease in Humans</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>101</volume>, <fpage>6212</fpage>&#x2013;<lpage>6216</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0400762101</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frost</surname>
<given-names>S. D. W.</given-names>
</name>
<name>
<surname>Magalis</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Kosakovsky Pond</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Neutral Theory and Rapidly Evolving Viral Pathogens</article-title>. <source>Mol. Biol. Evol.</source> <volume>35</volume>, <fpage>1348</fpage>&#x2013;<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/msy088</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shamier</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Bogers</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Den Hartog</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gommers</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nieuwkoop</surname>
<given-names>N. N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Variants of Concern Partially Escape Humoral but Not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees</article-title>. <source>Sci. Immunol.</source> <volume>6</volume>, <fpage>eabj1750</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abj1750</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershoni</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Roitburd-Berman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Siman-Tov</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Tarnovitski Freund</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Epitope Mapping: The First Step in Developing Epitope-Based Vaccines</article-title>. <source>BioDrugs</source> <volume>21</volume>, <fpage>145</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.2165/00063030-200721030-00002</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Seow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huettner</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kouphou</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Acors</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Neutralization Potency of Monoclonal Antibodies Recognizing Dominant and Subdominant Epitopes on SARS-CoV-2 Spike Is Impacted by the B.1.1.7 Variant</article-title>. <source>Immunity</source> <volume>54</volume>, <fpage>1276</fpage>&#x2013;<lpage>1289</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2021.03.023</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamre</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Procknow</surname>
<given-names>J.&#x20;J.</given-names>
</name>
</person-group> (<year>1966</year>). <article-title>A New Virus Isolated from the Human Respiratory Tract</article-title>. <source>Proc. Soc. Exp. Biol. Med.</source> <volume>121</volume>, <fpage>190</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-121-30734</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Carabelli</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>E. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Variants, Spike Mutations and Immune Escape</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>19</volume>, <fpage>409</fpage>&#x2013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haste Andersen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Prediction of Residues in Discontinuous B-Cell Epitopes Using Protein 3D Structures</article-title>. <source>Protein Sci.</source> <volume>15</volume>, <fpage>2558</fpage>&#x2013;<lpage>2567</lpage>. <pub-id pub-id-type="doi">10.1110/ps.062405906</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herr&#xe1;ez</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Biomolecules in the Computer: Jmol to the rescue</article-title>. <source>Biochem. Mol. Biol. Educ.</source> <volume>34</volume>, <fpage>255</fpage>&#x2013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1002/bmb.2006.494034042644</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hevener</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Babaoglu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>S. W.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase</article-title>. <source>J.&#x20;Chem. Inf. Model.</source> <volume>49</volume>, <fpage>444</fpage>&#x2013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1021/ci800293n</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holm</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Mapping the Protein Universe</article-title>. <source>Science</source> <volume>273</volume>, <fpage>595</fpage>&#x2013;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1126/science.273.5275.595</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hulswit</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>De Haan</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>B. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Coronavirus Spike Protein and Tropism Changes</article-title>. <source>Adv. Virus. Res.</source> <volume>96</volume>, <fpage>29</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.004</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jerne</surname>
<given-names>N. K.</given-names>
</name>
</person-group> (<year>1960</year>). <article-title>Immunological Speculations</article-title>. <source>Annu. Rev. Microbiol.</source> <volume>14</volume>, <fpage>341</fpage>&#x2013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.mi.14.100160.002013</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapikian</surname>
<given-names>A. Z.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>H. D.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Kelly</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Dees</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Mcintosh</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>1969</year>). <article-title>Isolation from Man of &#x201C;avian Infectious Bronchitis Virus-like&#x201d; Viruses (Coronaviruses) Similar to 229E Virus, with Some Epidemiological Observations</article-title>. <source>J.&#x20;Infect. Dis.</source> <volume>119</volume>, <fpage>282</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/119.3.282</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelley</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>M. J.&#x20;E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Protein Structure Prediction on the Web: a Case Study Using the Phyre Server</article-title>. <source>Nat. Protoc.</source> <volume>4</volume>, <fpage>363</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2009.2</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemp</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gayed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jahun</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Evolution during Treatment of Chronic Infection</article-title>. <source>Nature</source> <volume>592</volume>, <fpage>277</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03291-y</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khare</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Azevedo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parajuli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gokulan</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data</article-title>. <source>Front. Artif. Intell.</source> <volume>4</volume>, <fpage>630955</fpage>. <pub-id pub-id-type="doi">10.3389/frai.2021.630955</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>A. M. Q.</given-names>
</name>
<name>
<surname>Lefkowitz</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Mushegian</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Dutilh</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Gorbalenya</surname>
<given-names>A. E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Changes to Taxonomy and the International Code of Virus Classification and Nomenclature Ratified by the International Committee on Taxonomy of Viruses (2018)</article-title>. <source>Arch. Virol.</source> <volume>163</volume>, <fpage>2601</fpage>&#x2013;<lpage>2631</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-018-3847-1</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Parida</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Variant Analysis of SARS-CoV-2 Genomes</article-title>. <source>Bull. World Health Organ.</source> <volume>98</volume>, <fpage>495</fpage>&#x2013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.2471/blt.20.253591</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ksiazek</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Erdman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Peret</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>348</volume>, <fpage>1953</fpage>&#x2013;<lpage>1966</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa030781</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kufareva</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Abagyan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Methods of Protein Structure Comparison</article-title>. <source>Methods Mol. Biol.</source> <volume>857</volume>, <fpage>231</fpage>&#x2013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-588-6_10</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ladner</surname>
<given-names>J.&#x20;T.</given-names>
</name>
<name>
<surname>Henson</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Engelbrektson</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>Z. W.</given-names>
</name>
<name>
<surname>Rahee</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Epitope-resolved Profiling of the SARS-CoV-2 Antibody Response Identifies Cross-Reactivity with Endemic Human Coronaviruses</article-title>. <source>Cell Rep. Med.</source> <volume>2</volume>, <fpage>100189</fpage>. <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100189</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses</article-title>. <source>Nat. Microbiol.</source> <volume>5</volume>, <fpage>562</fpage>&#x2013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Structure, Function, and Evolution of Coronavirus Spike Proteins</article-title>. <source>Annu. Rev. Virol.</source> <volume>3</volume>, <fpage>237</fpage>&#x2013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G. F.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Bat-to-human: Spike Features Determining &#x27;host Jump&#x27; of Coronaviruses SARS-CoV, MERS-CoV, and beyond</article-title>. <source>Trends Microbiol.</source> <volume>23</volume>, <fpage>468</fpage>&#x2013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2015.06.003</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madhi</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Baillie</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cutland</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Voysey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koen</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Fairlie</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Efficacy of the ChAdOx1&#x20;nCoV-19 Covid-19 Vaccine against the B.1.351 Variant</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>384</volume>, <fpage>1885</fpage>&#x2013;<lpage>1898</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2102214</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kode</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bhojak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Karunakaran</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Manoharan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Immunodominant T-cell Epitopes From the SARS-CoV-2 Spike Antigen Reveal Robust Pre-Existing T-cell Immunity in Unexposed Individuals</article-title>. <source>Sci. Rep.</source> <volume>11</volume>, <fpage>13164</fpage>. </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercatelli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>F. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Geographic and Genomic Distribution of SARS-CoV-2 Mutations</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>, <fpage>1800</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2020.01800</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millet</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Host Cell Proteases: Critical Determinants of Coronavirus Tropism and Pathogenesis</article-title>. <source>Virus. Res.</source> <volume>202</volume>, <fpage>120</fpage>&#x2013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.11.021</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mallery</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Albecka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Cattin-Ortol&#xe1;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luptak</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Furin Cleavage of SARS-CoV-2 Spike Promotes but Is Not Essential for Infection and Cell-Cell Fusion</article-title>. <source>Plos Pathog.</source> <volume>17</volume>, <fpage>e1009246</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1009246</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poland</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Ovsyannikova</surname>
<given-names>I. G.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Immunity: Review and Applications to Phase 3 Vaccine Candidates</article-title>. <source>Lancet</source> <volume>396</volume>, <fpage>1595</fpage>&#x2013;<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)32137-1</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robson</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Computers and Viral Diseases. Preliminary Bioinformatics Studies on the Design of a Synthetic Vaccine and a Preventative Peptidomimetic Antagonist Against the SARS-CoV-2 (2019-nCoV, COVID-19) Coronavirus</article-title>. <source>Comput. Biol. Med.</source> <volume>119</volume>, <fpage>103670</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiomed.2020.103670</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pye</surname>
<given-names>V. E.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Seow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>K. W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Can Recruit a Heme Metabolite to Evade Antibody Immunity</article-title>. <source>Sci. Adv.</source> <volume>7</volume>, <fpage>eabg7607</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abg7607</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvatori</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Luberto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maffei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aurisicchio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roscilli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Palombo</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2 SPIKE PROTEIN: an Optimal Immunological Target for Vaccines</article-title>. <source>J.&#x20;Transl. Med.</source> <volume>18</volume>, <fpage>222</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-020-02392-y</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanyaolu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Okorie</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marinkovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haider</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Abbasi</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Jaferi</surname>
<given-names>U.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The Emerging SARS-CoV-2 Variants of Concern</article-title>. <source>Ther. Adv. Infect. Dis.</source> <volume>8</volume>, <fpage>20499361211024372</fpage>. <pub-id pub-id-type="doi">10.1177/20499361211024372</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sewell</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Why Must T&#x20;Cells Be Cross-Reactive</article-title>. <source>Nat. Rev. Immunol.</source> <volume>12</volume>, <fpage>669</fpage>&#x2013;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1038/nri3279</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stankov</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Cossmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonifacius</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dopfer-Jablonka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Godecke</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Humoral and Cellular Immune Responses against SARS-CoV-2 Variants and Human Coronaviruses after Single BNT162b2 Vaccination</article-title>. <source>Clin. Infect. Dis.</source> <pub-id pub-id-type="doi">10.1093/cid/ciab555</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tay</surname>
<given-names>M. Z.</given-names>
</name>
<name>
<surname>Poh</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>R&#xe9;nia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Macary</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>L. F. P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The trinity of COVID-19: Immunity, Inflammation and Intervention</article-title>. <source>Nat. Rev. Immunol.</source> <volume>20</volume>, <fpage>363</fpage>&#x2013;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomaszewski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Devries</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Norsworthy</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release</article-title>. <source>Evol. Bioinform. Online</source> <volume>16</volume>, <fpage>1176934320965149</fpage>. <pub-id pub-id-type="doi">10.1177/1176934320965149</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vehlow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stehr</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Winkelmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Petzold</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dinse</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>CMView: Interactive Contact Map Visualization and Analysis</article-title>. <source>Bioinformatics</source> <volume>27</volume>, <fpage>1573</fpage>&#x2013;<lpage>1574</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btr163</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vojtek</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Buchy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Hoet</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Would Immunization Be the Same without Cross-Reactivity</article-title>. <source>Vaccine</source> <volume>37</volume>, <fpage>539</fpage>&#x2013;<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.12.005</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Predicting Protein Contact Map Using Evolutionary and Physical Constraints by Integer Programming</article-title>. <source>Bioinformatics</source> <volume>29</volume>, <fpage>i266</fpage>&#x2013;<lpage>i273</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt211</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Tsoi</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia</article-title>. <source>J.&#x20;Virol.</source> <volume>79</volume>, <fpage>884</fpage>&#x2013;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.79.2.884-895.2005</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Natural Polymorphisms Are Present in the Furin Cleavage Site of the SARS-CoV-2 Spike Glycoprotein</article-title>. <source>Front. Genet.</source> <volume>11</volume>, <fpage>783</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2020.00783</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Govindarajoo</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Template-based Protein Structure Prediction in CASP11 and Retrospect of I-TASSER in the Last Decade</article-title>. <source>Proteins</source> <volume>84</volume>, <fpage>233</fpage>&#x2013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1002/prot.24918</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaki</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Van Boheemen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bestebroer</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>A. D. M. E.</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>R. A. M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>367</volume>, <fpage>1814</fpage>&#x2013;<lpage>1820</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa1211721</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Skolnick</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>TM-Align: A Protein Structure Alignment Algorithm Based on the TM-Score</article-title>. <source>Nucleic. Acids. Res.</source> <volume>33</volume>, <fpage>2302</fpage>&#x2013;<lpage>2309</lpage>. </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>382</volume>, <fpage>727</fpage>&#x2013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2001017</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>